MedTrace Logo

Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer

NCT06068101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 274

Last updated 2023-10-05

No results posted yet for this study

Summary

Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies. A higher prevalence of thyroid nodules and non-toxic multinodular goiter was described in patients with PA compared to those with essential hypertension (EH). A single study showed an association between PA and papillary thyroid cancer (PTC), but without a paired control group. Objective: To assess PA prevalence in a transversal cohort of patients with PTC and EH compared to a paired control group with HT.

Conditions

  • Thyroid Cancer, Papillary
  • Primary Aldosteronism

Interventions

DIAGNOSTIC_TEST

Secreening test for primary aldosteronism and Confirmatory Testing

Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone \> or = 10 ng/dL and aldosterone to renin ratio \> or = 2 ng/dL/uUI/mL

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2022-12-01
Completion
2023-08-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068101 on ClinicalTrials.gov